Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longeveron Inc. - Class A Common stock (NQ: LGVN )

1.650 +0.050 (+3.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Why Is Perion Network (PERI) Stock Down 39% Today?
Perion Network stock is falling on Monday after the company's preliminary Q1 revenue results failed to impress PERI investors. 
Via InvestorPlace
Why Is U Power (UCAR) Stock Up 69% Today?
U Power stock is heading higher on Monday with heavy trading of UCAR as investors celebrate plans for a battery swap service. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Is Longeveron (LGVN) Stock Up 82% Today?
Longeveron stock is up on Monday after the company announced plans for a proposed public offering of LGVN shares and warrants. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Recap: Longeveron Q4 Earnings
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Earnings Preview For Longeveron
Via Benzinga
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares rose sharply during today’s pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update
Via Investor Brand Network
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. 
Via Benzinga
Researchers Link Type 2 Diabetes to Heightened Alzheimer’s Risk
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Study Links Parkinson’s Onset in Rocky Mountain Area to Agricultural Pesticides
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results, Corporate Update
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update
Via Investor Brand Network
BioMedNewsBreaks — Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients
Via Investor Brand Network
Study Links Ramadan Fasting to Lower Risk of Chronic Disease Development
Via Investor Brand Network
BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society (ORS) 2024 Annual Meeting
BioRestorative Therapies (NASDAQ: BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease and metabolic conditions such as obesity and... 
Via Benzinga
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech’s Investigational Alzheimer’s Treatment Shows Positive Trial Results
--News Direct-- 
Via News Direct
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to slow the effects of life-threatening and chronic aging-related conditions using cellular therapies, is making inroads with... 
Via Benzinga
Longeveron Inc.’s (NASDAQ: LGVN) Long-Term Follow-Up Data from Its ELPIS I Clinical Trial Presented at the 2023 Annual Scientific Sessions of the American Heart Association
Via Investor Brand Network
BioMedNewsBreaks – H.C. Wainwright & Co. Reiterates ‘Buy’ Rating, $6 PT on Longeveron (NASDAQ: LGVN)
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Dietician Tips for Boosting Muscle Mass, Living Longer
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Granted US Patent Allowance for Key Technology Behind Lead Investigation Product
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.